NASDAQ:TGTX - TG Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.37 -0.21 (-3.76 %)
(As of 10/21/2018 04:00 PM ET)
Previous Close$5.37
Today's Range$5.26 - $5.6799
52-Week Range$4.95 - $17.35
Volume1.20 million shs
Average Volume2.60 million shs
Market Capitalization$444.74 million
P/E Ratio-2.81
Dividend YieldN/A
Beta1.34
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Debt-to-Equity RatioN/A
Current Ratio3.68
Quick Ratio3.68

Price-To-Earnings

Trailing P/E Ratio-2.81
Forward P/E Ratio-2.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales2,964.96
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book5.65

Profitability

EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-97,412.51%
Return on Equity-177.79%
Return on Assets-128.51%

Miscellaneous

Employees75
Outstanding Shares82,820,000
Market Cap$444.74 million

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.04. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 177.79% and a negative net margin of 97,412.51%. View TG Therapeutics' Earnings History.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for TG Therapeutics.

What price target have analysts set for TGTX?

4 brokers have issued twelve-month price targets for TG Therapeutics' stock. Their forecasts range from $12.00 to $38.00. On average, they anticipate TG Therapeutics' stock price to reach $26.00 in the next year. This suggests a possible upside of 384.2% from the stock's current price. View Analyst Price Targets for TG Therapeutics.

What is the consensus analysts' recommendation for TG Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our price target of $38 is based on the net present value of our revenue forecast through 2026, applying a 55% probability of success (POS) for ublituximab in CLL, a 45% POS for umbralisib in 25% POS for both ublituximab and umbralisib in NHL. We use a 4x price/sales multiple, and 1Q18 fully diluted net cash of $1.61/ share to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x." (8/7/2018)
  • 2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (7/26/2018)
  • 3. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)

Who are some of TG Therapeutics' key competitors?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 52)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 36)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $5.37.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $444.74 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 75 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is http://www.tgtherapeutics.com.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  446 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  638
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Featured Article: Float

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel